Dan Nomura
@DanNomura
Professor of Chemical Biology and Molecular Therapeutics at UC Berkeley; Departments of Chemistry and Molecular and Cell Biology; Co-Director of @MTI_UCB
Cool paper from @fischerlab1 and @kdonovan1008 on unveiling the hidden interactome of CRBN molecular glues! nature.com/articles/s4146…
Grateful to everyone who brought #BayAreaBiotechDay to life yesterday at @UCBerkeley! It was incredible to see the energy in the room and the cutting-edge advances shared by leaders in both academia and industry. Excited to see what’s next for biotech!
Big day for the David lab! 🎉 Our @MolecularCell paper is out today- huge congrats to first authors @IfeAkano & Jake Hebert for leading this beautiful study uncovering SMARCA3 as a novel H3 E3 ligase that shapes heterochromatin regulation in colorectal cancer 🤩
Online Now: The SWI/SNF-related protein SMARCA3 is a histone H3K23 ubiquitin ligase that regulates H3K9me3 in cancer dlvr.it/TLz0Lw
Don't miss the chance to apply for our next round of Endeavor Award funding! Letters of intent are due September 3.
📢Funding Opportunity!📢 The Mark Foundation is now accepting letters of intent for the Endeavor Award. ✅$3 million in cancer research funding over 3 years ✅Open to multidisciplinary teams of 3+ investigators ✅Worldwide call LOIs are due Sept 3: themarkfoundation.org/endeavor/
🚨 Bay Area Biotech Day hits @UCBerkeley next week (7/22)! Hear Nobel laureate Carolyn Bertozzi + leaders from Denali, Calico, Frontier, Nurix, Arcus & more on the next wave of drug discovery. 🧬 Posters, panels & networking. #Biotech #DrugDiscovery #UCBerkeley
What could be more fun that connecting @UCBerkeley students and trailblazing biotechs, and hearing @CarolynBertozzi deliver an inspiring Keynote?
🚨 Bay Area Biotech Day hits @UCBerkeley next week (7/22)! Hear Nobel laureate Carolyn Bertozzi + leaders from Denali, Calico, Frontier, Nurix, Arcus & more on the next wave of drug discovery. 🧬 Posters, panels & networking. #Biotech #DrugDiscovery #UCBerkeley
New preprint w/ the Dupage lab! FSP1 KO in Tregs / Tcells promotes tumor suppression, highlighting the therapeutic value & single-agent potential of FSP1 inhibition. A new paradigm for targeting ferroptosis in the immune system (not just in cancer cells). biorxiv.org/content/10.110…
Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly endpoints.news/biotechs-q2-nu…
A great post for raising money from VCs.... "Best Practices for Pitching, Geared Towards First-Time Founders" - from @AtlasVenture's @AimeeRaleigh13 ... lifescivc.com/2025/07/best-p…
A new #CRISPR Cures center, funded by $20M from @czi and led by @UrnovFyodor, will create 8 custom therapies for patients in the next 3 years. “Our goal is to aggressively walk the walk of CRISPR platformization,” Urnov told me. More in @endpts: endpoints.news/crispr-cures-c…
Cool paper on rational design of CDK12/13 and BRD4 molecular glue degraders from Nathanael Gray's lab: onlinelibrary.wiley.com/doi/10.1002/an…
A global genetic interaction map of a human cell reveals conserved principles of genetic networks | bioRxiv biorxiv.org/content/10.110…
Cool paper from Monte Rosa on Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition | Science science.org/doi/10.1126/sc…
This paper now published in @ACSCentSci!! pubs.acs.org/doi/10.1021/ac…
Excited to highlight our latest @biorxivpreprint by graduate student @L__Orreo on the discovery of a covalent degradative handle that acts through two unique cysteines C173 and C178, on the frequent-hitting E3 ligase DCAF16 that can be used to modularly design monovalent and…
Distribution is and always will be the edge
Mindshare is everything - something I've learned watching @kalshi and @polymarket. I've used both platforms and I'd argue that kalshi is the better product. - I hate bridging to polygon, or paying fees on moonpay for polymarket. Kalshi lets you just connect a bank account. -…
🚀 Bay Area Biotech Day lands @UCBerkeley 7/22! Hear Nobel Laureate Carolyn Bertozzi + leaders from Denali Therapeutics, Calico Labs, Frontier Medicines & more leaders in biotechnology unveil the next wave in drug discovery. Scan the QR on the flyer to register now! 🧬🥂
Check out our lab's newest pub, live in ACS ChemBio! We report interesting CRBN-independent activities of N-alkylated lenalidomide derivatives, or "capped imides." Congrats to Farah and all of the authors! 🥳💐 pubs.acs.org/doi/10.1021/ac…
Cool follow-up story from Cravatt lab on covalent targeting of NONO: Structural and mechanistic analysis of covalent ligands targeting the RNA-binding protein NONO | bioRxiv biorxiv.org/content/10.110…
Awesome being back in Boston for #ChemBiointhePub ahead of the Bioorganic Chemistry GRC!
Happy to present our latest paper with @pottslab & @Amgen in @J_A_C_S by co-first authors @C_M_Zammit & Cory Nadel on the discovery of a direct-acting covalent destabilizing degrader of AR and the undruggable truncation variant of AR, AR-V7, in androgen-independent prostate…
